Sheila Frame, vice president and head of biopharmaceuticals, North America, at Sandoz, discusses patient concerns about switching to a biosimilar.
Transcript:
So I think the whole issue of switching stable patients certainly continues to be the highlight of many debates, both for physicians as well as for associations and patient groups.
And so I do think it's something that certainly at Sandoz we take very seriously. I do think though, you know, if you think about a patient who's been well controlled on an originator product, they've already been subjected to biosimilar switching. Every batch that they've had over whatever period of time has been a biosimilar.
And so I think that they're—I totally support and understand what the concern would be. Don't mess with my—especially if you're subjected to pain. Nobody wants to go back to that world when you talk to some of these patients and the patient associations. You just wouldn't want to put anybody through that.
At the same time, given the requirements under the [Biologics Price Competition and Innovation Act, BPCIA], I think also just what we actually do in order to prove the safety and efficacy, I really think it's worth a try. I really do. I think I would say to a patient, you know, be open, give it a shot, and then the value that's created in the system to free up the capacity to fund those new innovations that are coming I think is probably worth taking the chance, in the appropriate context.
I mean, I'm not a physician. So I'm not going to give medical advice, but I definitely think that given the publications and the experience, we've had years of pretty massive switches in many of the European countries, and we haven't seen any issues emerge over time. So, while, again, I understand the concern, I just think that the safety and efficacy that we've been able to prove and demonstrate with the kind of exposure that we've had is probably worth the try.
PBM Evolution Toward Value-Based Care Shifts to Transparent Pharmacy Pricing
March 30th 2025Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health, predict pharmacy benefit managers (PBMs) will evolve toward value-based care, mirroring the broader shift toward open-cost structures.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Empowering Vulnerable Populations: The Path to Equitable Biologic Therapy Access
December 22nd 2024Elie Bahou, PharmD, senior vice president and system chief pharmacy officer at Providence, discusses strategies to improve equitable access to biologic therapies, including tiered formularies, income-based cost sharing, patient assistance programs, and fostering payer partnerships.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.